Denali Therapeutics, a biopharmaceutical company based in South San Francisco, develops therapies for neurodegenerative diseases, with seven clinical candidates and ongoing studies for conditions like ALS and Parkinson's disease. The company went public on December 8, 2017, and has 375 employees.
Denali Therapeutics (DNLI) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Denali Therapeutics's actual EPS was -$0.78, missing the estimate of -$0.70 per share, resulting in a -11.43% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
